Total number of projects: 4
As coordinator: 1
As participant: 3
Sole participant: 0
Coordinator / Participant Ratio: 0.33*
Total project funding [€]: | Projects [No]: | |||||
---|---|---|---|---|---|---|
Year: | coordinator* | participant* | per partner | as coordinator | as participant | |
2013 | 0 | 5.380.170 | 268.368 | 1 | ||
2012 | 2.998.217 | 11.959.436 | 1.186.336 | 1 | 2 |
Total number of partners: 539
Partner loyalty:
Frequent Partner: (> 2 projects): 113
Rare Partner: 426
Frequent / Rare Partner Ratio: 0.27
Start date | Project | acronym | role | funding | partners |
---|---|---|---|---|---|
2013-01-01 | Phase I/II Gene Therapy Trial of Fanconi anemia patients with a new Orphan Drug consisting of a lentiviral vector carrying the FANCA gene: A Coordinated International Action | EUROFANCOLEN | participant | 5.380.170 | 11 |
2012-11-01 | Glioma Actively Personalized Vaccine Consortium | GAPVAC | participant | 5.970.436 | 13 |
2012-11-01 | Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation | BIO-DRIM | participant | 5.989.000 | 17 |
2012-09-01 | Benznidazol and Triazol REsearch group for Nanomedicine and Innovation on Chagas diseasE | BERENICE | coordinator | 2.998.217 | 8 |